141 related articles for article (PubMed ID: 27905688)
1. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis.
Ananth P; Werger A; Voss S; Rodriguez-Galindo C; Janeway KA
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27905688
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Kawashima H; Kawai A; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Oct; 50(11):1274-1281. PubMed ID: 32700733
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-Eluting Intra-Arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease.
Elnekave E; Atar E; Amar S; Bruckheimer E; Knizhnik M; Yaniv I; Dujovny T; Feinmesser M; Ash S
J Vasc Interv Radiol; 2018 Oct; 29(10):1376-1382. PubMed ID: 30075974
[TBL] [Abstract][Full Text] [Related]
5. Response of progressive fibromatosis to therapy with liposomal doxorubicin.
Wehl G; Rossler J; Otten JE; Boehm N; Uhl M; Kontny U; Niemeyer C
Onkologie; 2004 Dec; 27(6):552-6. PubMed ID: 15591714
[TBL] [Abstract][Full Text] [Related]
6. Advanced aggressive fibromatosis: Effective palliation with chemotherapy.
Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
Acta Oncol; 2011 Apr; 50(3):455-61. PubMed ID: 20799916
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin treatment of an intra-abdominal desmoid tumour in a patient with familial adenomatous polyposis.
Risum S; Bülow S
Colorectal Dis; 2003 Nov; 5(6):585-6. PubMed ID: 14617246
[No Abstract] [Full Text] [Related]
8. Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.
Liu X; Wang H; Wu X; Hong X; Luo Z
Invest New Drugs; 2018 Feb; 36(1):114-120. PubMed ID: 29170886
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results.
Muñoz A; Maldonado M; Pardo N; Fernández JM; Vela E; Cubells J
Pediatr Blood Cancer; 2004 Aug; 43(2):152-5. PubMed ID: 15236282
[No Abstract] [Full Text] [Related]
11. Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
Ferrari A; Orbach D; Affinita MC; Chiaravalli S; Corradini N; Meazza C; Bisogno G; Casanova M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27472. PubMed ID: 30270493
[TBL] [Abstract][Full Text] [Related]
12. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
[TBL] [Abstract][Full Text] [Related]
13. Desmoid-type fibromatosis of the head and neck in children: A changing situation.
Paul A; Blouin MJ; Minard-Colin V; Galmiche L; Coulomb A; Corradini N; Boutroux H; Van den Abbeele T; Leboulanger N; Denoyelle F; Garabedian EN; Couloigner V; Orbach D
Int J Pediatr Otorhinolaryngol; 2019 Aug; 123():33-37. PubMed ID: 31059930
[TBL] [Abstract][Full Text] [Related]
14. Oral vinorelbine in young patients with desmoid-type fibromatosis.
Kornreich L; Orbach D; Nicolas N; Brisse HJ; Berlanga P; Defachelles AS; Mansuy L; Verite C; Saumet L; Karanian M; Corradini N
Tumori; 2023 Oct; 109(5):511-518. PubMed ID: 37114926
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin consolidation therapy.
Hamm W
Oncologist; 2006; 11(7):855; author reply 855-6. PubMed ID: 16880247
[No Abstract] [Full Text] [Related]
16. [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].
Szmit S; Filipiak KJ; Litwiniuk M; Opolski G; Wysocki P; Zaborska B; Krzakowski M
Kardiol Pol; 2016; 74(9):1031-6. PubMed ID: 27654476
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series.
Glas M; Koch H; Hirschmann B; Jauch T; Steinbrecher A; Herrlinger U; Bogdahn U; Hau P
Oncology; 2007; 72(5-6):302-7. PubMed ID: 18198491
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
19. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
